Oncology Search
Oncology Oncology
multiple%20myeloma
MULTIPLE MYELOMA

Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion.

It accounts for 1-2% of all cancers worldwide & mostly affects patients at ages 65-74 years old.

Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams.

 

Multiple Myeloma Drug Information

Drug Information

Indication: Agammaglobulinemia/hypogammaglobulinemia. Combined therapy w/ antibiotics in severe bacterial or viral infecti...

Indication: Osteoporosis in postmenopausal women at increased risk of fracture. Increases bone mineral density & reduc...

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: In combination w/ bortezomib, melphalan, prednisone for patients w/ newly diagnosed multiple myeloma ineligibl...

Indication: Anemia associated w/ chronic renal failure in adults & paed on dialysis. Anemia & reduction of transfu...

Indication: Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has pro...

Indication: Multiple myeloma. Mantle cell lymphoma.

Indication: Multiple myeloma & mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy.

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Tab: Multiple myeloma, advanced ovarian adenocarcinoma, breast carcinoma, polycythaemia rubra vera. Inj: Local...

1  /  5
1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
ESMO calls for cancer patients to be prioritized for COVID-19 vaccination
Dr Margaret Shi, 4 days ago

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).